NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.15. The biopharmaceutical company earned $8.04 million during the quarter, compared to analysts' expectations of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Dicerna Pharmaceuticals.

8 brokers have issued 12 month price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $29.43 in the next year. This suggests a possible upside of 14.2% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Media headlines about DRNA stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Dicerna Pharmaceuticals.

Some companies that are related to Dicerna Pharmaceuticals include Perrigo (PRGO), The Medicines (MDCO), Dr.Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Reata Pharmaceuticals (RETA), Horizon Therapeutics (HZNP), Allakos (ALLK), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), FibroGen (FGEN), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR) and Blueprint Medicines (BPMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Array Biopharma (ARRY), Strongbridge Biopharma (SBBP), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Sorrento Therapeutics (SRNE), Ergomed (ERGO), Progenics Pharmaceuticals (PGNX) and Equity Commonwealth (EQC).

Dicerna Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (2.61%), Eagle Asset Management Inc. (2.58%), Carillon Tower Advisers Inc. (1.64%), Emerald Advisers LLC (1.28%), Emerald Mutual Fund Advisers Trust (1.14%) and Millennium Management LLC (0.55%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Brian K Halak, Dennis Langer, James B Weissman, John B Green and Peter Kolchinsky. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Barclays PLC, SG Americas Securities LLC, State Street Corp, Alps Advisors Inc. and Claro Advisors LLC. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, James B Weissman, John B Green and Peter Kolchinsky. View Insider Buying and Selling for Dicerna Pharmaceuticals.

DRNA stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Millennium Management LLC, Alberta Investment Management Corp, California Public Employees Retirement System, Squarepoint Ops LLC, Zurcher Kantonalbank Zurich Cantonalbank and California State Teachers Retirement System. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $25.77.

Dicerna Pharmaceuticals has a market capitalization of $1.76 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]